Mehra Golshan
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
Metzger-Filho O, von Minckwitz G, Rastogi P, Li L, Cheng L, Maag D, Wolmark N, Denkert C, Symmans W, Geyer C, Loibl S, Sikov W, Golshan M, Collier K, Asad S, Ansell P, Watson M, Bae J, Cherian M, O'Shaughnessy J, Untch M, Rugo H, Huober J, Stover D. Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. NPJ Breast Cancer 2021; 7:142.
11.11.2021Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
11.11.2021NPJ Breast Cancer 2021; 7:142
Metzger-Filho Otto, von Minckwitz Gunter, Rastogi Priya, Li Lang, Cheng Lijun, Maag David, Wolmark Norman, Denkert Carsten, Symmans W Fraser, Geyer Charles E, Loibl Sibylle, Sikov William M, Golshan Mehra, Collier Katharine, Asad Sarah, Ansell Peter J, Watson Mark, Bae Junu, Cherian Mathew, O'Shaughnessy Joyce, Untch Michael, Rugo Hope S, Huober Jens, Stover Daniel G
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Filho O, Rugo H, Huober J, Golshan M, Sikov W, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Untch M, O'Shaughnessy J, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, Bae J, Collier K, Cherian M, Symmans W. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:603-608.
01.04.2021Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
01.04.2021JAMA Oncol 2021; 7:603-608
Filho Otto Metzger, Rugo Hope S, Huober Jens, Golshan Mehra, Sikov William M, von Minckwitz Gunter, Rastogi Priya, Maag David, Wolmark Norman, Denkert Carsten, Untch Michael, O'Shaughnessy Joyce, Stover Daniel G, Asad Sarah, Ansell Peter J, Watson Mark, Loibl Sibylle, Geyer Charles E, Bae Junu, Collier Katharine, Cherian Mathew, Symmans W Fraser
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial
Golshan M, Sikov W, Geyer C, von Minckwitz G, Metzger-Filho O, Sullivan D, Maag D, Ansell P, Wolmark N, Rugo H, O'Shaughnessy J, Huober J, Loibl S, Wong S, Untch M. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial. Eur J Surg Oncol 2019; 46:223-228.
05.10.2019Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial
05.10.2019Eur J Surg Oncol 2019; 46:223-228
Golshan Mehra, Sikov William M, Geyer Charles E, von Minckwitz Gunter, Metzger-Filho Otto, Sullivan Danielle M, Maag David, Ansell Peter, Wolmark Norman, Rugo Hope S, O'Shaughnessy Joyce, Huober Jens, Loibl Sibylle, Wong Stephanie M, Untch Michael
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Loibl S, Liu X, Symmans W, Rastogi P, Metzger Filho O, Ponce Lorenzo J, McIntyre K, Wolmark N, Sullivan D, Maag D, von Minckwitz G, Golshan M, Huober J, McKee M, Rugo H, Sikov W, Untch M, O'Shaughnessy J, Geyer C. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018; 19:497-509.
28.02.2018Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
28.02.2018Lancet Oncol 2018; 19:497-509
Loibl Sibylle, Liu Xuan, Symmans W Fraser, Rastogi Priya, Metzger Filho Otto, Ponce Lorenzo Jose J, McIntyre Kristi, Wolmark Norman, Sullivan Danielle, Maag David, von Minckwitz Gunter, Golshan Mehra, Huober Jens, McKee Mark D, Rugo Hope S, Sikov William M, Untch Michael, O'Shaughnessy Joyce, Geyer Charles E